Validated biomarkers used for AD diagnosis are: (i) cerebrospinal fluid (CSF) analysis of Aβ42, t-tau, and p-tau accumulation, and (ii) positron emission tomography (PET) scan (amyloid PET and tau PET). The gene discussed is MAPT; the disease is Alzheimer disease.